1. • Andreoni M, Marcotullio S, Puro V, De Carli G, Tambussi G, Nozza S, et al. An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaim Project. New Microbiol; 2015: 443–90. A comprehensive review on several aspects of integrase inhibitors.
2. Panel on Antiretroviral Guidelines for Adults. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf [Last accessed 31/10/2016]
3. European AIDS Clinical, Society. EACS Guidelines Version 8.1 October 2016. Available at: http://www.eacsociety.org/files/guidelines_8.1-english.pdf [Last accessed 31/10/2016].
4. Tsiang M, Jones GS, Goldsmith J, Mulato A, Hansen D, Kan E, et al. Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile. Antimicrob Agents Chemother 2016.
5. Margolis DA, Brinson CC, Smith GH, de Vente J, Hagins DP, Eron JJ, et al. Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial. Lancet Infect Dis. 2015;15:1145–55.